Skip to main content
CCSB logo

CCSB — Investor Relations & Filings

Ticker · 1762 ISIN · TW0001762003 TW Manufacturing
Open in API
Filings indexed 1,608 across all filing types
Latest filing 2020-06-22 Environmental & Social …
Country TW Taiwan
Listing TW 1762

About CCSB

www.ccsb.com.tw

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB) is a specialized manufacturer of Active Pharmaceutical Ingredients (APIs) with a history dating back to 1964. The company focuses on the research, development, and large-scale production of high-quality APIs, particularly in the therapeutic areas of oncology, antifungal treatments, and immunosuppressants. CCSB offers a broad service portfolio that includes cGMP-compliant contract manufacturing and toll manufacturing. By leveraging advanced chemical synthesis and biotechnology platforms, the company provides tailored solutions to global pharmaceutical partners. CCSB adheres to rigorous international quality standards and environmental, health, and safety protocols, ensuring the reliable supply of critical medicinal components for the global healthcare market.

Recent filings

Filing Released Lang Actions
108年企業社會責任報告書
Environmental & Social Information Classification · 95% confidence The document is a brief tabular summary from a public information observation station, listing a company's voluntary report submission. The report is identified as a sustainability report covering the period 108/01/01 to 108/12/31 (likely a fiscal year), prepared according to GRI standards, which are commonly used for Environmental, Social, and Governance (ESG) reporting. The document is short (1226 characters) and provides links to the sustainability report files rather than containing the report itself. This matches the description of an Environmental & Social Information report (ESG report). Therefore, the appropriate classification is 'SR'.
2020-06-22 Chinese
109年年報及股東會資料 — 2020_1762_20200529F05.pdf
Annual Report Classification · 95% confidence The document is a detailed record of the Annual General Meeting (AGM) of 中化合成生技股份有限公司 for the year 109 (2020), including the meeting minutes, attendance, reports presented, resolutions passed, voting results, and appendices such as the business report, financial statements, and auditor's report. It contains comprehensive financial data, management reports, and audit opinions. The presence of detailed financial statements, auditor's report, and management discussion indicates this is the official Annual Report document rather than just an announcement or minutes alone. The document length (15,000 characters) and content depth confirm it is not a brief announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2019
2020-06-15 Chinese
109年年報及股東會資料 — 2019_1762_20200529FE4.pdf
Regulatory Filings
2020-06-15 Chinese
109年年報及股東會資料 — 2020_1762_20200529F17.pdf
Major Shareholding Notification Classification · 100% confidence The document contains detailed information about the top ten shareholders of a company, including their shareholdings, relationships among shareholders, and related parties. It is a disclosure of major shareholding information, showing percentages and relationships among significant shareholders as of a specific date (March 31, 2020). There is no indication of financial statements, management discussion, or other report types. The content matches the definition of a Major Shareholding Notification, which reports changes or details in significant share ownership levels.
2020-06-15 Chinese
109年年報及股東會資料 — 2019_1762_20200529F04.pdf
Regulatory Filings
2020-06-15 Chinese
109年年報及股東會資料 — 2020_1762_20200529F13.pdf
Regulatory Filings
2020-06-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.